Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Identifieur interne : 007153 ( Main/Merge ); précédent : 007152; suivant : 007154

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Auteurs : H T Benamer [Royaume-Uni] ; J. Patterson ; D J Wyper ; D M Hadley ; G J Macphee ; D G Grosset

Source :

RBID : pubmed:10928580

English descriptors

Abstract

The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using 123I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. 123I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease. The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. 123I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.

PubMed: 10928580

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:10928580

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.</title>
<author>
<name sortKey="Benamer, H T" sort="Benamer, H T" uniqKey="Benamer H" first="H T" last="Benamer">H T Benamer</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow, Scotland, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow, Scotland</wicri:regionArea>
<wicri:noRegion>Scotland</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Patterson, J" sort="Patterson, J" uniqKey="Patterson J" first="J" last="Patterson">J. Patterson</name>
</author>
<author>
<name sortKey="Wyper, D J" sort="Wyper, D J" uniqKey="Wyper D" first="D J" last="Wyper">D J Wyper</name>
</author>
<author>
<name sortKey="Hadley, D M" sort="Hadley, D M" uniqKey="Hadley D" first="D M" last="Hadley">D M Hadley</name>
</author>
<author>
<name sortKey="Macphee, G J" sort="Macphee, G J" uniqKey="Macphee G" first="G J" last="Macphee">G J Macphee</name>
</author>
<author>
<name sortKey="Grosset, D G" sort="Grosset, D G" uniqKey="Grosset D" first="D G" last="Grosset">D G Grosset</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10928580</idno>
<idno type="pmid">10928580</idno>
<idno type="wicri:Area/PubMed/Corpus">003F45</idno>
<idno type="wicri:Area/PubMed/Curation">003F45</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004010</idno>
<idno type="wicri:Area/Ncbi/Merge">000306</idno>
<idno type="wicri:Area/Ncbi/Curation">000306</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000306</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Benamer H:correlation:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">007153</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.</title>
<author>
<name sortKey="Benamer, H T" sort="Benamer, H T" uniqKey="Benamer H" first="H T" last="Benamer">H T Benamer</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow, Scotland, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow, Scotland</wicri:regionArea>
<wicri:noRegion>Scotland</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Patterson, J" sort="Patterson, J" uniqKey="Patterson J" first="J" last="Patterson">J. Patterson</name>
</author>
<author>
<name sortKey="Wyper, D J" sort="Wyper, D J" uniqKey="Wyper D" first="D J" last="Wyper">D J Wyper</name>
</author>
<author>
<name sortKey="Hadley, D M" sort="Hadley, D M" uniqKey="Hadley D" first="D M" last="Hadley">D M Hadley</name>
</author>
<author>
<name sortKey="Macphee, G J" sort="Macphee, G J" uniqKey="Macphee G" first="G J" last="Macphee">G J Macphee</name>
</author>
<author>
<name sortKey="Grosset, D G" sort="Grosset, D G" uniqKey="Grosset D" first="D G" last="Grosset">D G Grosset</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Brain Mapping</term>
<term>Carrier Proteins (physiology)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Corpus Striatum (radionuclide imaging)</term>
<term>Dominance, Cerebral (physiology)</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Female</term>
<term>Humans</term>
<term>Iodine Radioisotopes (diagnostic use)</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Nortropanes (diagnostic use)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Tropanes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en">
<term>Iodine Radioisotopes</term>
<term>Nortropanes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en">
<term>Carrier Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Dominance, Cerebral</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Brain Mapping</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Tropanes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using 123I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. 123I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease. The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. 123I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007153 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007153 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:10928580
   |texte=   Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:10928580" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024